Cargando…

Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments

BACKGROUND: The progression process of lung cancer can be accelerated by M2 macrophages. However, genes that affect M2 macrophage polarization remain unidentified. METHODS: The Cancer Genome Atlas, Gene Expression Omnibus, and Arrayexpress databases were used to obtain open-access data. The analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhen, Yu, Jiachen, Yang, Zhuo, Du, Kangming, Chen, Yuewei, Zhou, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797692/
https://www.ncbi.nlm.nih.gov/pubmed/36591493
http://dx.doi.org/10.3389/fonc.2022.1096449
_version_ 1784860735151538176
author Zeng, Zhen
Yu, Jiachen
Yang, Zhuo
Du, Kangming
Chen, Yuewei
Zhou, Lei
author_facet Zeng, Zhen
Yu, Jiachen
Yang, Zhuo
Du, Kangming
Chen, Yuewei
Zhou, Lei
author_sort Zeng, Zhen
collection PubMed
description BACKGROUND: The progression process of lung cancer can be accelerated by M2 macrophages. However, genes that affect M2 macrophage polarization remain unidentified. METHODS: The Cancer Genome Atlas, Gene Expression Omnibus, and Arrayexpress databases were used to obtain open-access data. The analysis of public data was mostly performed with R studio. The RNA levels of specific genes were detected using quantitative real-time PCR. The proliferation ability of the cells was assessed by CCK8, colony formation, and EdU assays. RESULTS: Based on the multiple datasets, we noticed a poor prognosis in patients with high M2 macrophage infiltration. There were 114 genes differentially expressed between high and low M2 macrophages infiltrated samples, regarded as M2 macrophage-related genes. Subsequently, a prognosis prediction signature consisting of ABHD5, HS3ST2, TM6SF1, CAPZA2, LEPROT, HNMT, and MRO was identified and presented a satisfactory performance. The pathway enrichment results revealed a positive correlation between riskscore and enrichment scores for most immunotherapy-related positive terms. Also, there might be an increase in genomic instability among patients at high risk. Interestingly, low risk patients are most likely to benefit from PD-1 therapy, while high risk patients may benefit from CTLA-4 therapy. Meanwhile, the estimated IC50 of seven drugs differs significantly between two risk groups, including Cisplatin, Docetaxel, Doxorubicin, Gefitinib, Paclitaxel, Sunitinib and Vinorelbine. Moreover, further experiments indicated that HNMT was overexpressed and can enhance the proliferation ability in lung cancer cells. CONCLUSIONS: In summary, our study identified the molecules significantly affecting M2 macrophage infiltration and identified a prognosis signature that robustly indicated patients prognosis. Moreover, we validated the cancer-promoting effect of HNMT using in vitro experiments.
format Online
Article
Text
id pubmed-9797692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97976922022-12-30 Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments Zeng, Zhen Yu, Jiachen Yang, Zhuo Du, Kangming Chen, Yuewei Zhou, Lei Front Oncol Oncology BACKGROUND: The progression process of lung cancer can be accelerated by M2 macrophages. However, genes that affect M2 macrophage polarization remain unidentified. METHODS: The Cancer Genome Atlas, Gene Expression Omnibus, and Arrayexpress databases were used to obtain open-access data. The analysis of public data was mostly performed with R studio. The RNA levels of specific genes were detected using quantitative real-time PCR. The proliferation ability of the cells was assessed by CCK8, colony formation, and EdU assays. RESULTS: Based on the multiple datasets, we noticed a poor prognosis in patients with high M2 macrophage infiltration. There were 114 genes differentially expressed between high and low M2 macrophages infiltrated samples, regarded as M2 macrophage-related genes. Subsequently, a prognosis prediction signature consisting of ABHD5, HS3ST2, TM6SF1, CAPZA2, LEPROT, HNMT, and MRO was identified and presented a satisfactory performance. The pathway enrichment results revealed a positive correlation between riskscore and enrichment scores for most immunotherapy-related positive terms. Also, there might be an increase in genomic instability among patients at high risk. Interestingly, low risk patients are most likely to benefit from PD-1 therapy, while high risk patients may benefit from CTLA-4 therapy. Meanwhile, the estimated IC50 of seven drugs differs significantly between two risk groups, including Cisplatin, Docetaxel, Doxorubicin, Gefitinib, Paclitaxel, Sunitinib and Vinorelbine. Moreover, further experiments indicated that HNMT was overexpressed and can enhance the proliferation ability in lung cancer cells. CONCLUSIONS: In summary, our study identified the molecules significantly affecting M2 macrophage infiltration and identified a prognosis signature that robustly indicated patients prognosis. Moreover, we validated the cancer-promoting effect of HNMT using in vitro experiments. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797692/ /pubmed/36591493 http://dx.doi.org/10.3389/fonc.2022.1096449 Text en Copyright © 2022 Zeng, Yu, Yang, Du, Chen and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Zhen
Yu, Jiachen
Yang, Zhuo
Du, Kangming
Chen, Yuewei
Zhou, Lei
Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title_full Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title_fullStr Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title_full_unstemmed Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title_short Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments
title_sort investigation of m2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: evidence from bioinformatic and experiments
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797692/
https://www.ncbi.nlm.nih.gov/pubmed/36591493
http://dx.doi.org/10.3389/fonc.2022.1096449
work_keys_str_mv AT zengzhen investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments
AT yujiachen investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments
AT yangzhuo investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments
AT dukangming investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments
AT chenyuewei investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments
AT zhoulei investigationofm2macrophagerelatedgeneaffectingpatientsprognosisanddrugsensitivityinnonsmallcelllungcancerevidencefrombioinformaticandexperiments